Editorial
doi: 10.1016/j.annonc.2021.03.002.
Epub 2021 Mar 17.
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer
Affiliations
- PMID: 33741444
- DOI: 10.1016/j.annonc.2021.03.002
Item in Clipboard
Editorial
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer
Ann Oncol.
2021 May.
Free article
No abstract available
Conflict of interest statement
Disclosure Outside submitted work TES reports personal fees from Takeda, AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, Daiichi Sankyo, Lilly, Medtronic, Puma Biotechnology, Janssen Oncology, and Regeneron. Grant support for clinical trials (institution) outside the submitted work from Genentech/Roche, Blueprint Medicines, AstraZeneca, Takeda, Advaxis, and Regeneron.
Comment on
-
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.Ann Oncol. 2021 May;32(5):620-630. doi: 10.1016/j.annonc.2021.02.012. Epub 2021 Feb 24. Ann Oncol. 2021. PMID: 33639216 Clinical Trial.
Similar articles
-
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.J Thorac Oncol. 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028. J Thorac Oncol. 2019. PMID: 31668326 No abstract available.
-
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192. Jpn J Clin Oncol. 2021. PMID: 33147606 Review.
-
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
-
Lorlatinib Outperforms Crizotinib in NSCLC.Cancer Discov. 2021 Jan;11(1):OF5. doi: 10.1158/2159-8290.CD-NB2020-110. Epub 2020 Dec 9. Cancer Discov. 2021. PMID: 33298467
-
Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.Expert Rev Clin Pharmacol. 2019 Mar;12(3):173-178. doi: 10.1080/17512433.2019.1570846. Epub 2019 Jan 30. Expert Rev Clin Pharmacol. 2019. PMID: 30657349 Review.
Cited by
-
Safety Profile and Hepatotoxicity of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Disproportionality Analysis Based on FDA Adverse Event Reporting System Database.Toxics. 2025 Mar 14;13(3):210. doi: 10.3390/toxics13030210. Toxics. 2025. PMID: 40137538 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
